Buchumschlag

First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer: final results from a prospective German study

Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-poin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Schneeweiss, Andreas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2016
In: Anticancer research
Year: 2016, Jahrgang: 36, Heft: 3, Pages: 967-974
ISSN:1791-7530
Online-Zugang:Verlag, Volltext: http://ar.iiarjournals.org/content/36/3/967
Volltext
Verfasserangaben:Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, Martin M. Hertz-Eichenrode, Winfried Schönegg, Claudia Schumacher, Andreas Kutscheidt, Claudia Kiewitz, Sandra Klawitter and Marcus Schmidt
Beschreibung
Zusammenfassung:Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-points were safety and efficacy [response rate, progression-free survival (PFS) and overall survival (OS)]. Results: Between May 2007 and September 2009, 865 patients received first-line bevacizumab plus paclitaxel for mBC, of whom 16% were aged ≥70 years and 9% had ECOG performance status of 2 or more. At data cut-off (median of 15.9 months' follow-up), the median PFS was 9.6 months [95% confidence interval (CI)=9.0-10.4 months] and the median OS was 21.6 months (95% CI=19.4-23.5 months). The most common non-haematological adverse drug reactions of grade 3 or more were pain (9%), hypertension (5%), sensory neuropathy (3%) and proteinuria (3%). Prolonged bevacizumab was well-tolerated. Conclusion: The efficacy and safety of first-line bevacizumab-paclitaxel in routine oncology practice is consistent with results from randomized trials.
Beschreibung:Gesehen am 13.05.2019
Beschreibung:Online Resource
ISSN:1791-7530

Ähnliche Einträge